Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma

Back to Search
Print
Bookmark Trial

NCT00635323

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Shanghai, , 200433, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatocellular Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Asian subjects with histologically or cytologically confirmed hepatocellular carcinoma

- Inoperable disease (unable to completely remove surgically, presence of extra-hepatic disease, main portal vein or hepatic vein involvement)

- Eastern Cooperative Oncology Group performance status of ?2

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Decompensated cirrhosis or stage C (Index>10) according to the Child-Pugh
Classification


- Current history of chronic diarrhoea


- Reproductive potential not using adequate contraceptive measures

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Hepatocellular CarcinomaStudy Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
NCT00699374
  1. Fountain Valley, California
  2. La Jolla, California
  3. La Jolla, California
  4. Orange, California
  5. San Diego, California
  6. Miami, Florida
  7. Ringgold, Georgia
  8. Iowa City, Iowa
  9. Crestview Hills, Kentucky
  10. Bronx, New York
  11. Cincinnati, Ohio
  12. Cincinnati, Ohio
  13. Cincinnati, Ohio
  14. Cincinnati, Ohio
  15. Cincinnati, Ohio
  16. Cincinnati, Ohio
  17. Fairfield, Ohio
  18. Hamilton, Ohio
  19. Chattanooga, Tennessee
  20. Franklin, Tennessee
  21. Gallatin, Tennessee
  22. Hermitage, Tennessee
  23. Hixson, Tennessee
  24. Lebanon, Tennessee
  25. Murfreesboro, Tennessee
  26. Nashville, Tennessee
  27. Nashville, Tennessee
  28. Nashville, Tennessee
  29. Nashville, Tennessee
  30. Smyrna, Tennessee
  31. Mechanicsville, Virginia
  32. Midlothian, Virginia
  33. Richmond, Virginia
  34. Richmond, Virginia
  35. Seattle, Washington
  36. Concord, New South Wales
  37. Elizabeth Vale, South Australia
  38. Woodville South, South Australia
  39. Melbourne, Victoria
  40. Parkville, Victoria
  41. Bruxelles,
  42. Bruxelles,
  43. Gent,
  44. Calgary, Alberta
  45. Vancouver, British Columbia
  46. Kingston, Ontario
  47. Toronto, Ontario
  48. Montreal, Quebec
  49. Hefei, Anhui
  50. Fuzhou City, Fujian
  51. Guangzhou, Guangdong
  52. Guangzhou, Guangdong
  53. Nanning, Guangxi
  54. Wuhan, Hubei
  55. Nanjing, Jiangsu
  56. Chengdu, Sichuan
  57. Hangzhou, Zhejiang
  58. Hangzhou, Zhejiang
  59. Beijing,
  60. Beijing,
  61. Bejing,
  62. Chong qing,
  63. Guangzhou,
  64. Nanjing,
  65. Shanghai,
  66. Amiens Cedex 1,
  67. Bordeaux Cedex,
  68. Clichy Cedex,
  69. Creteil Cedex,
  70. Lille Cedex,
  71. Nice Cedex 2,
  72. Paris Cedex 13,
  73. Paris,
  74. St Herblain Cedex,
  75. Strasbourg Cedex,
  76. Toulouse,
  77. Vandoeuvre Les Nancy Cedex,
  78. Villejuif Cedex,
  79. Hamburg,
  80. Hannover,
  81. Mainz,
  82. Muenchen,
  83. Hong Hong,
  84. Kowloon,
  85. Shatin, New Territories,
  86. Tuen Mun, New Territories,
  87. Meldola, FC
  88. Bari,
  89. Bologna,
  90. Cattolica (RN),
  91. Milano,
  92. Milano,
  93. Padova,
  94. Pavia,
  95. Ravenna,
  96. Rimini,
  97. Nagoya, Aichi
  98. Chiba city, Chiba
  99. Kashiwa-shi, Chiba
  100. Kurume city, Fukuoka
  101. Gifu-shi, Gifu
  102. Sapporo-shi, Hokkaido
  103. Nishinomiya, Hyogo
  104. Kanazawa city, Ishikawa
  105. Omura-shi, Nagasaki
  106. Osaka-shi, Osaka-fu
  107. Osaka-Sayama, Osaka
  108. Izunokuni-shi, Shizuoka
  109. Bunkyo-ku, Tokyo
  110. Chiyoda-ku, Tokyo
  111. Chuo-ku, Tokyo
  112. Itabashi-ku, Tokyo
  113. Mitaka-shi, Tokyo
  114. Setagaya-ku, Tokyo
  115. Okayama,
  116. Chonju, Chonbuk
  117. Goyang-si, Gyeonggi-do
  118. Hwasun-gun, Jeollanam-do
  119. Busan,
  120. Daegu,
  121. Daegu,
  122. Incheon,
  123. Seoul,
  124. Seoul,
  125. Seoul,
  126. Seoul,
  127. Seoul,
  128. Lembah Pantai, Kuala Lumpur
  129. Subang Jaya, Selangor
  130. Kuala Lumpur,
  131. Cebu City, Cebu
  132. Cebu City,
  133. Davao City,
  134. Manila,
  135. Manila,
  136. Quezon City,
  137. Quezon City,
  138. Quezon City,
  139. Warszawa,
  140. Warszawa,
  141. Chelyabinsk,
  142. Pyatigorsk,
  143. St.Petersburg,
  144. Singapore,
  145. Singapore,
  146. Parktown,
  147. Sabadell, Barcelona
  148. Santander, Cantabria
  149. Palma de Mallorca, Illes Balears
  150. El Palmar, Murcia
  151. Sevilla,
  152. Linkoping,
  153. Pu-Tz City, Chai-Yi
  154. Kwei-Shan, Taoyuan
  155. Changhua,
  156. Kaohsiung,
  157. Kaohsiung,
  158. Taichung City,
  159. Taichung,
  160. Tainan,
  161. Tainan,
  162. Taipei,
  163. Taipei,
  164. Bangkok Noi, Bangkok
  165. Ptumwan, Bangkok
  166. Amphoe Mueang, Chiang Mai
  167. Ankara,
  168. Istanbul,
  169. Cambridge, Cambridgeshire
  170. London,
  171. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hepatocellular CarcinomaSafety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
NCT00635323
  1. Shanghai,
  2. Hong Kong SAR,
  3. Seoul,
  4. Seoul,
  5. Seoul,
  6. Seoul,
  7. Keelung,
  8. Taipei,
  9. Taipei,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hepatocellular CarcinomaA Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
NCT03289533
  1. Nagoya, Aichi
  2. Iizuka, Fukuoka
  3. Osaka-Sayama, Osaka
  4. Chuo-ku, Tokyo
  5. Mitaka-shi, Tokyo
  6. Musashino, Tokyo
  7. Fukuoka,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Hepatocellular CarcinomaAxitinib For The Treatment Of Advanced Hepatocellular Carcinoma
NCT01210495
  1. Berkeley, California
  2. La Jolla, California
  3. La Jolla, California
  4. Orange, California
  5. San Diego, California
  6. Orlando, Florida
  7. Tampa, Florida
  8. Ann Arbor, Michigan
  9. Omaha, Nebraska
  10. Las Vegas, Nevada
  11. Las Vegas, Nevada
  12. Philadelphia, Pennsylvania
  13. Philadelphia, Pennsylvania
  14. Gent,
  15. Liège,
  16. Hefei, Anhui
  17. Guangzhou, Guangdong
  18. Nan Jing, Jiangsu
  19. Nanjing, Jiangsu
  20. Hangzhou, Zhejiang
  21. Beijing,
  22. Shanghai,
  23. Amiens,
  24. Bordeaux Cedex,
  25. Caen, cedex 05,
  26. Clichy,
  27. Lyon Cedex 04,
  28. Marseille,
  29. Montpellier Cedex 05,
  30. Nice,
  31. Paris,
  32. Rennes,
  33. Toulouse Cedex,
  34. Berlin,
  35. Bonn,
  36. München,
  37. Hong Kong,
  38. Shatin, N.T.,
  39. Budapest,
  40. Szeged,
  41. Bologna,
  42. Bologna,
  43. Lido Di Camaiore (LU),
  44. Meldola (FC),
  45. Pavia,
  46. Roma,
  47. Roma,
  48. Siena,
  49. Nagoya, Aichi
  50. Chiba City, Chiba
  51. Gifu-shi, Gifu
  52. Kanazawa, Ishikawa
  53. Osaka-Sayama, Osaka
  54. Suntou-gun, Shizuoka
  55. Chiyoda-Ku, Tokyo
  56. Itabashi-Ku, Tokyo
  57. Kofu-Shi,
  58. Goyang-si,
  59. Seoul,
  60. Seoul,
  61. Banska Bystrica,
  62. Bratislava,
  63. Poprad,
  64. Poprad,
  65. Changhua,
  66. Kaohsiung,
  67. Taichung,
  68. Tainan,
  69. Tainan,
  70. Taipei,
  71. Taoyuan,
  72. Withington, Manchester
  73. Liverpool,
  74. Liverpool,
  75. London,
  76. London,
  77. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
Official Title  ICMJE A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable Hepatocellular Carcinoma
Brief Summary To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Hepatocellular
Intervention  ICMJE Drug: Irinotecan plus capecitabine
Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
Study Arms  ICMJE Experimental: A
Intervention: Drug: Irinotecan plus capecitabine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: March 5, 2008)		73
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Asian subjects with histologically or cytologically confirmed hepatocellular carcinoma
  • Inoperable disease (unable to completely remove surgically, presence of extra-hepatic disease, main portal vein or hepatic vein involvement)
  • Eastern Cooperative Oncology Group performance status of ?2

Exclusion Criteria:

  • Decompensated cirrhosis or stage C (Index>10) according to the Child-Pugh Classification
  • Current history of chronic diarrhoea
  • Reproductive potential not using adequate contraceptive measures
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China,   Hong Kong,   Korea, Republic of,   Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00635323
Other Study ID Numbers  ICMJE XRP4174/2501
A5961080
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP